Human tumors are characterized by recurring chromosomal abnormalities. Molecular analysis of the genes that are located at the breakpoints of a number of recurring chromosomal abnormalities has revealed that alterations in the level of expression of these genes, or in the properties of the encoded proteins resulting from the chromosomal rearrangement, play an integral role in the process of malignant transformation. Dr. Le Beau’s research interests are (1) to identify the recurring chromosomal abnormalities in human tumors, and to correlate specific chromosomal abnormalities with morphological and clinical features of the neoplastic disease, such as response to therapy and survival; (2) to identify the oncogenes and tumor suppressor genes whose function is altered as a result of recurring chromosomal abnormalities using molecular techniques, and to examine their function in normal and malignant cells; (3) to develop and validate mouse models for the genetic mutations involved in human leukemogenesis, and to use these models for pre-clinical drug testing and for the identification of genetic mutations associated with drug-resistance; (4) to identify the secondary cooperating genetic mutations and the molecular pathways involved in leukemogenesis; and (5) to examine the relationship of chromosomal fragile sites (loci which are prone to undergo breakage and, rearrangement) and cancer-specific breakpoints. Dr. Le Beau also works on gene localization projects using cytogenetic techniques (e.g. FISH), and has collaborated with Graeme Bell in localizing a number of the genes implicated in susceptibility to MODY, type 1 and type 2 diabetes.